Pancreatic Ductal Adenocarcinoma Clinical Trials
Pancreatic Ductal Adenocarcinoma clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for pancreatic Ductal Adenocarcinoma. Corterve aggregates actively recruiting Pancreatic Ductal Adenocarcinoma studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Pancreatic Ductal Adenocarcinoma studies
- PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)NCT06673017PHASE1PanTher TherapeuticsPancreatic Ductal AdenocarcinomaNewport Beach, California
- OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaNCT07089940EARLY_PHASE1OHSU Knight Cancer InstituteLocally Advanced Pancreatic Ductal AdenocarcinomaPortland, Oregon
- Lead-212 PSV359 Therapy for Patients With Solid TumorsNCT06710756PHASE1, PHASE2Perspective TherapeuticsPancreatic Ductal AdenocarcinomaLos Angeles, California
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)NCT06428409PHASE1, PHASE2Merck Sharp & Dohme LLCColorectal CancerLos Angeles, California
- Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct AdenocarcinomaNCT06831136PHASE2The University of Texas Health Science Center, HoustonPancreatic Ductal AdenocarcinomaHouston, Texas
- AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsNCT07454642PHASE1Avacta Life Sciences LtdVulvar AdenocarcinomaScottsdale, Arizona
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07562152PHASE3Immuneering CorporationPancreatic CancerHuntsville, Alabama
- DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic CancerNCT07705919PHASE1, PHASE2Ohio State University Comprehensive Cancer CenterBorderline Resectable Pancreatic Ductal AdenocarcinomaColumbus, Ohio
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal AdenocarcinomaNCT07490301PHASE2, PHASE3AbbVieMetastatic Pancreatic Ductal AdenocarcinomaNew Haven, Connecticut
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07491445PHASE3Revolution Medicines, Inc.Pancreatic CancerPhoenix, Arizona
- Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerNCT06423326PHASE2Georgetown UniversityBorderline Resectable Pancreatic Ductal AdenocarcinomaWashington D.C., District of Columbia
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2NCT06219941PHASE2AstraZenecaGastric CancerOrange, California
Pancreatic Ductal Adenocarcinoma trials by state
Pancreatic Ductal Adenocarcinoma trials by metro
Frequently asked questions
- How do I find recruiting Pancreatic Ductal Adenocarcinoma clinical trials?
- Browse the actively recruiting Pancreatic Ductal Adenocarcinoma studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Pancreatic Ductal Adenocarcinoma clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Pancreatic Ductal Adenocarcinoma clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.